In this review for each menin inhibitor, we examine pharmacologic characteristics, clinical efficacy, safety profile, and their potential to redefine the treatment paradigm for NPM1m and KMT2Ar AML. This evidence concerns the gene MEN1 and acute myeloid leukemia.